Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise in preventing deadly blood clot relapses in japanese patients

NCT ID NCT04074187

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a drug called caplacizumab in 21 Japanese adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare condition causing dangerous blood clots. Participants received caplacizumab alongside standard treatments like plasma exchange and steroids. The goal was to see if the drug could prevent the disease from coming back. Early results suggest it may help control the disorder, but larger studies are needed to confirm safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
caplacizumab
What this could lead to
If successful, this could offer a new treatment option to prevent life-threatening blood clots and relapses in Japanese patients with acquired TTP.
What could go wrong
This was a small, early-phase study with only 21 participants, so results may not apply to all patients. Side effects like bleeding are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired thrombotic thrombocytopenic purpura thrombotic thrombocytopenic purpura

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THROMBOTIC THROMBOCYTOPENIC PURPURA

Contacts and locations

Locations

  • Investigational Site Number 3920001

    Kitakyushu-Shi, Japan

  • Investigational Site Number 3920002

    Kumamoto, Japan

  • Investigational Site Number 3920003

    Kurashiki-Shi, Japan

  • Investigational Site Number 3920005

    Maebashi, Japan

  • Investigational Site Number 3920006

    Sendai, Japan

  • Investigational Site Number 3920007

    Kashihara-shi, Japan

  • Investigational Site Number 3920009

    Iruma-Gun, Japan

  • Investigational Site Number 3920010

    Kyoto, Japan

  • Investigational Site Number 3920011

    Osaka, Japan

  • Investigational Site Number 3920013

    Kawasaki-Shi, Japan

  • Investigational Site Number 3920014

    Kanazawa, Japan

  • Investigational Site Number 3920015

    Nagoya, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.